Develops epinephrine nasal sprays for anaphylaxis.
Jun 2026Revenue $117M/yrExpenses $333M/yr
No trendCash runway ≈ 9 months from Jun 2026
Figures by year
When will ARS Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $117M and expenses $333M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $84.3M | $264M | −$179M |
| Dec 2024 | $89.1M | $92.2M | −$3.08M |
| Dec 2023 | $30.0K | $67.5M | −$67.5M |
| Dec 2022 | $1.32M | $36.8M | −$35.5M |
| Dec 2021 | $5.51M | $25.0M | −$19.5M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.